Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948375 | 0.91 | MEN1 (0.51) | GAAALOX5MEN1KMT2AALDH1A1 | |
| SCHEMBL1917727 | 0.84 | GAA (0.48) | GAAALOX5MEN1KMT2AALDH1A1 | |
| SCHEMBL24470880 | 0.82 | TSHR (0.64) | GAAMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29630224 | 0.82 | TSHR (0.64) | GAAMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL14217294 | 0.82 | ABCB1 (0.43) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29014544 | 0.81 | GAA (0.56) | GAAALOX5MEN1KMT2AALDH1A1 | |
| SCHEMBL1918655 | 0.80 | ANO1 (0.44) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1918033 | 0.80 | ALOX5 (0.79) | GAAALOX5MEN1KMT2AALDH1A1 | |
| SCHEMBL1918982 | 0.79 | KCNH2 (0.52) | — | |
| SCHEMBL10241488 | 0.78 | ALOX5 (0.44) | GAAALOX5MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2831066-B1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2831066-B1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2326633-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9096580-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096580-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150141395-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-20150141395-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-21 | — | — | US | disclosed |
| EP-2831066-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2015-02-04 | — | — | EP | disclosed |
| EP-2649067-B1 | BENZOFURANE DERIVATIVES FOR THE TREATMENT OF HEPATITITS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2649067-B1 | BENZOFURANE DERIVATIVES FOR THE TREATMENT OF HEPATITITS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2012003164-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-05 | — | — | WO | disclosed |
| US-8048887-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-20 | — | — | US | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-7994171-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2326633-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100093694-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| WO-2010030592-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141395-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HAVCR2, UGT2B7, GOT1 | GAA 456/4885ALOX5 1234/4885MEN1 4819/4885 |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GAA 162/4885ALOX5 1368/4885MEN1 4676/4885 |
| US-20100093694-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GAA 162/4885ALOX5 1368/4885MEN1 4676/4885 |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GAA 162/4885ALOX5 1368/4885MEN1 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.